Isa, Abubakar S

Isa, Abubakar S. I. Jatau, Ismaeel Yunusa, Mustapha Mohammed, Al-Kassim H. Mohammed, Abubakar M. Isa, Abubakar S. Wada, Kabiru A. Gulma, Inuwa Bello, Sani Malami, Godpower C. Michael and Basheer AZ. Chedi in Therapeutic Advances in Infectious Disease sj-xlsx-1-tai-10.1177_20499361211039379 C Supplemental material for Knowledge assessment of anti-snake venom among healthcare practitioners in northern Nigeria sj-xlsx-1-tai-10.1177_20499361211039379.xlsx (58K) GUID:?4EFD9A07-BCAA-4D96-8167-81348AAA6FE9 sj-xlsx-1-tai-10.1177_20499361211039379 for Knowledge assessment of anti-snake venom among healthcare practitioners in northern Nigeria by Auwal A. Bala, Abubakar I. Jatau, Ismaeel Yunusa, Mustapha Mohammed, Al-Kassim H. Mohammed, Abubakar M. Isa, Abubakar S. Wada, Kabiru A. Gulma, Inuwa Bello, Sani Malami, Godpower C. Michael and Basheer AZ. Chedi Ziyuglycoside I in Therapeutic Advances in Infectious Disease This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Abstract Introduction: Anti-snake venom (ASV) is the standard therapy for the management of snakebite envenoming (SBE). Therefore, the knowledge of ASV among healthcare practitioners (HCPs) is essential for achieving optimal clinical outcomes in snakebite management. This study aimed to assess knowledge of ASV among the HCPs in northern Nigeria. Methods: We conducted Ziyuglycoside I a cross-sectional study involving eligible HCPs from different healthcare settings in northern Nigeria. The participants were recruited into the study using a combination of online (via Google Form) and face-to-face paper-based survey methods. The ASV knowledge of the respondents was measured using a validated anti-snake venom knowledge assessment tool (AKAT). Inadequate overall knowledge of ASV was defined as scores of 0C69.9%, and 70C100% were considered adequate overall knowledge scores. The predictors of ASV knowledge were determined using multiple logistic regression. Results: Three hundred and thirty-one (331) eligible HCPs were included in the study analysis (310 from online and 21 from paper-based survey). Overall, an estimated 12.7% of the participants had adequate knowledge of ASV. Adequate ASV knowledge was higher among physicians compared with other HCPs (21.7%; 2?=?8.1; 91.0%; 2?=?17.7, 78.3%; 2?=?13.7.0; (%) /th /thead 1.Previous training on ASV120 (36.3)2.Previously administered/dispensed ASV63 (19.0)3.Major components of ASV272 (82.2)4.Various forms of ASV179 (54.1)5.Common dosage formulations of ASV84 (25.4)6.Appropriate adult dose for ASV189 (57.1)7.Monovalent ASV for multiple snake types286 (86.4)8.Appropriate ASV for snakebite of unknown species302 (91.2)9.Common side effects of ASV62 (18.7)10.Treatments for ASV reactions91 (27.5)11.ASV contain immunoglobulins295 (89.1)12.ASV is specific to snake species234 (70.7)13.ASV is the only standard treatment for snake envenoming234 (70.7)14.ASV can have a severe hypersensitivity reaction314 (94.9)15.ASV is cheap in Nigeria259 (78.2)16.ASV is administered orally317 (95.8)17.ASV is administered intravenously291 (87.9)18.ASV is administered intramuscularly133 (40.2)19.ASV is administered intradermally239 (72.2) Open in a separate window ASV, antisnake venom. Factors associated with ASV knowledge among HCPs Of all the variables analyzed in the bivariate analysis, three experienced a em p /em ? ?0.25 and were included in the MLR. The final model of the MLR Rabbit Polyclonal to C1R (H chain, Cleaved-Arg463) demonstrates that respondents without previous teaching (aOR, 0.365; 95% CI, 0.182C0.729; em p /em ?=?0.004) and who have not previously administered/ dispensed ASV (aOR, 0.306; 95% CI, 0.150C0.625; em p /em ? ?0.001) were less likely to have adequate ASV knowledge. No possible collinearity in the included variables was observed. Relationships between variables were also assessed, and none were recognized. The model fit for the data was superb; the HosmerCLemeshow test was significant ( em p /em ?=?0.428). The final model was offered as modified ORs with 95% CIs and related em p /em -ideals in Table 4. Table 4. Multiple logistic regression C final model. thead th align=”remaining” rowspan=”1″ colspan=”1″ Variables /th th align=”remaining” rowspan=”1″ colspan=”1″ *Adjusted OR (95% CI) /th th align=”remaining” rowspan=”1″ colspan=”1″ em p /em -Value /th /thead Earlier teaching on ASV?No0.365 (0.182C0.729)0.004?Yes1 (Research)Previously administered/dispensed ASV?No0.306 (0.150C0.625) 0.001?Yes1 (Research) Open in Ziyuglycoside I a separate windowpane Hosmer and Lemeshow test, em p /em ?=?0.428; Omnibus checks of model coefficients, em p /em ? ?0.001; classification table, 87.3%. *Modified for teaching on ASV and administration or dispensing of ASV. ASV, snake antivenom; CI, confidence interval; OR, odds ratio. Availability, cost, and logistics Data display that most of the HCPs facilities did not distribute ASV in the last 24?weeks (69.4%), from July 2017 to May 2019. The common brands of ASV distributed were EchiTab (36.8%), Premium Pan Africa (27.5%), and Vins (16.8%). The quantities distributed primarily were less than 10 (68.3%) vials. The majority were polyvalent (73.7%), liquid preparations (72.6%), obtained mainly.